-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, new crown oral drugs have continued to usher in good news
On November 4, Merck announced that its new crown oral drug Molnupiravir was approved in the UK for the treatment of mild to moderate new crown pneumonia
On November 5, Pfizer followed suit and announced that its new oral drug Paxlovid in the Phase 2/3 clinical EPIC-HR study interim analysis reduced hospitalization or mortality by 89%
From: Pfizer official website
Vaccine stocks and neutralizing antibody concept stocks once again fell across the board following the positive development of oral drugs
Vaccine stocks share price changes in the past 5 days
Moderna is the vaccine stock that has suffered the most recently
With turbulence on the new crown track, Pfizer has undoubtedly become a true leader, achieving dual coverage of vaccines and oral drugs